Chloroquine for Reducing Immune Activation in HIV- Infected Individuals
Public ClinicalTrials.gov record NCT00819390. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase II, Double Blind, Randomized, Exploratory Study of Chloroquine for Reducing HIV-Associated Immune Activation
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
HIV is characterized by frequent immune system activation. Early in the course of infection the body establishes an immune activation "set point" related to the amount of HIV in the blood stream. This set point affects the rate of CD4 cell loss. Without CD4 cells, or with very low levels of CD4 cells, the body cannot fight off illness. This is known as immunodeficiency. If left untreated HIV can lead to extreme immunodeficiency and AIDS. Evidence suggests that by decreasing the rate of immune system activation, immune deficiency progression could be prevented. The purpose of this study is to learn how well chloroquine can reduce the level of immune activation and to test the safety and tolerance of chloroquine in people infected with HIV.
Study identification
- NCT ID
- NCT00819390
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 70 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Feb 28, 2009
- Primary completion
- Jan 31, 2013
- Completion
- Apr 30, 2013
- Last update posted
- Oct 12, 2014
2009 – 2013
United States locations
- U.S. sites
- 15
- U.S. states
- 12
- U.S. cities
- 14
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Alabama Therapeutics CRS (5801) | Birmingham | Alabama | 35294 | — |
| Ucsd, Avrc Crs (701) | San Diego | California | 92103 | — |
| University of Colorado Hospital CRS (6101) | Aurora | Colorado | 80045 | — |
| Georgetown University CRS (GU CRS) (1008) | Washington D.C. | District of Columbia | 20007 | — |
| Johns Hopkins Adult AIDS CRS (201) | Baltimore | Maryland | 21205 | — |
| Massachusetts General Hospital ACTG CRS (101) | Boston | Massachusetts | 02114 | — |
| Washington University CRS (2101) | St Louis | Missouri | 63110 | — |
| Cornell CRS (7804) | New York | New York | 10011 | — |
| Unc Aids Crs (3201) | Chapel Hill | North Carolina | 27514 | — |
| Univ. of Cincinnati CRS (2401) | Cincinnati | Ohio | 45267 | — |
| Case CRS (2501) | Cleveland | Ohio | 44106 | — |
| MetroHealth CRS (2503) | Cleveland | Ohio | 44109 | — |
| Hosp. of the Univ. of Pennsylvania CRS (6201) | Philadelphia | Pennsylvania | 19104 | — |
| Pittsburgh CRS (1001) | Pittsburgh | Pennsylvania | 15213 | — |
| Vanderbilt Therapeutics CRS (3652) | Nashville | Tennessee | 37204 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00819390, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Oct 12, 2014 · Synced Sep 2, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT00819390 live on ClinicalTrials.gov.